Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...

Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Guardant Health (GH – Research Report), with a price target ...

Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved ...

Guardant Health (NASDAQ:GH – Free Report) had its target price lifted by Morgan Stanley from $42.00 to $52.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the ...

Principal Financial Group Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 8.0% in ...